HBV—LP在乙型肝炎治疗终点及预后判断中的应用研究  

The application study of HBV - LP in hepatitis B treatment terminal and prognosis

作　　者：李桂霞[1] 

机构地区：[1]菏泽市立医院检验科,山东菏泽274031

出　　处：《医学检验与临床》2012年第6期45-47,共3页Medical Laboratory Science and Clinics

摘　　要：目的探讨HBV—LP作为乙肝治疗终点判断及预后评价方面的效果。方法收集本院临床诊断为慢性乙型肝炎并排除其他肝病者176例，随机分为两组，血清HBV—DNA阴转和血清HBV—LP阴转作为抗病毒治疗的终点。结果第9个月开绐，两组的复发率出现显著差异（P〈0．05）。第24个月存在非常显著性差异（P〈0．01）。故认为第一组复发率比第二组明显高。结论HBV—DNA阴转的患者在停药后不久表现为治疗后的高复发率，给临床乙型肝炎的治疗造成了很大的障碍。因此。寻找新的，更为理想的判断乙肝治疗终点的标志物对于降低乙肝治疗后的复发，提高乙肝的治愈率，减少肝炎向肝硬化和肝癌发展具有重要的意义。Objective To Explore the HBV - LP as a hepatitis B u：eatment effect of the end of judgment and prognostic evaluation. Metods Collection of hospital clinical diagnosis of chranie hepatitis B and exclude other liver diseases and 176 cases were randomly divided into two groups, serum HBV-DNA negative conversion of serum HBV - LP overcast as the end point of antiviral therapy. Resdts 9 months to open its population, the recurrence rate of the two groups appear significant difference （p 〈 0.05）. The first 24 months, there is a very significant differences （p 〈 0.01 ）. The first group, recurrence rate is significantly higher than the second group. Conclusion HBV- DNA negative conversion patients shortly after stopping the high relapse rate after treatment, causing a great obstacle to the clinical hepatitis B treatment. Therefore. Looking for new and more desirable to determine the end point of the treatment of hepatitis B markers has important implications for reducing the recurrence of hepatitis B after treatment to improve the cure rate of hepatitis B to reduce hepatitis to cirrhosis and liver cancer development.

关 键 词：HBV—LP 治疗终点 预后 

分 类 号：R512.62[医药卫生—内科学]